Skip to main content
. 2022 Jun 7;40(32):4424–4431. doi: 10.1016/j.vaccine.2022.05.090

Fig. 3.

Fig. 3

IgG binding and spike neutralisation at 3060 days following illness onset among participants with mild COVID-19 who did (N = 16) and did not (N = 36) develop PASC Difference in 30–60 day WT-D614G spike protein neutralising IgG titers and anti-spike and anti-RBD IgG binding titers between those who did and did not develop PASC with mild COVID-19. The mean effects on neutralising and IgG titers from those who did and did not develop PASC were estimated using a Bayesian multilevel model. Differences in posterior means were mean-centred such that effect sizes shown can be compared on a common scale (top row). Distributions of serum spike protein neutralising IgG titers (bottom left), spike binding (bottom middle) and RBD binding (bottom right) displayed such that each dot represents one participant. RBD = Receptor binding domain. PASC = Post-acute sequelae of COVID-19.